Bristol-Myers unloads old-school plant as it readies for CAR-T future

Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy even as it prepares to move into a whole new manufacturing arena after its $74 billion buyout of Celgene.